This study is a Phase I, open label, multi-center study of to evaluate the safety and efficacy of JMT101 in patients with advanced solid tumor.
Name: JMT101
Name: JMT101
Description: Blood samples will be collected from subjects post treatment for assessment to detect the presence of anti-drug antibodies(ADA) and neutralizing antibodies by electrochemical luminescence(ECL).
Measure: Immunogenicity profile of JMT101. Time: From enrollment until 30 days after the last doseDescription: The content of RAS(reticular activating system), EGFR(epidermal growth factor receptor), BRAF(B-Raf proto-oncogene) gene will be detected.
Measure: Potential biomarkers detected in plasma or tumor issue DNA. Time: From enrollment up to disease progression, an average of 1 yearAllocation: Non-Randomized
Sequential Assignment
There is one SNP
The content of RAS(reticular activating system), EGFR(epidermal growth factor receptor), BRAF(B-Raf proto-oncogene) gene will be detected.. Inclusion Criteria: - Monotherapy: Pathologically or cytologically confirmed, advanced solid tumor, harboring RAS wild type; Combined with chemotherapy: Pathologically or cytologically confirmed, locally advanced /metastatic colorectal cancer, harboring RAS and BRAF V600E wild type. --- V600E ---
- Receiving an investigational product in another clinical study within 4 weeks; - History of serious systemic diseases; - Pregnancy or lactating wo Inclusion Criteria: - Monotherapy: Pathologically or cytologically confirmed, advanced solid tumor, harboring RAS wild type; Combined with chemotherapy: Pathologically or cytologically confirmed, locally advanced /metastatic colorectal cancer, harboring RAS and BRAF V600E wild type. --- V600E ---